Search by Drug Name or NDC
NDC 70518-2749-05 CEFIXIME 400 mg/1 Details
CEFIXIME 400 mg/1
CEFIXIME is a ORAL CAPSULE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by REMEDYREPACK INC.. The primary component is CEFIXIME.
MedlinePlus Drug Summary
Cefixime is used to treat certain infections caused by bacteria such as bronchitis (infection of the airway tubes leading to the lungs); gonorrhea (a sexually transmitted disease); and infections of the ears, throat, tonsils, and urinary tract. Cefixime is in a class of medications called cephalosporin antibiotics. It works by killing bacteria. Antibiotics such as cefixime will not work for colds, flu, or other viral infections. Using antibiotics when they are not needed increases your risk of getting an infection later that resists antibiotic treatment.
Related Packages: 70518-2749-05Last Updated: 05/05/2024
MedLinePlus Full Drug Details: Cefixime
Product Information
NDC | 70518-2749 |
---|---|
Product ID | 70518-2749_0bc451ca-3379-8240-e063-6294a90a3000 |
Associated GPIs | |
GCN Sequence Number | n/a |
GCN Sequence Number Description | n/a |
HIC3 | n/a |
HIC3 Description | n/a |
GCN | n/a |
HICL Sequence Number | n/a |
HICL Sequence Number Description | n/a |
Brand/Generic | n/a |
Proprietary Name | CEFIXIME |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | CEFIXIME |
Product Type | HUMAN PRESCRIPTION DRUG |
Dosage Form | CAPSULE |
Route | ORAL |
Active Ingredient Strength | 400 |
Active Ingredient Units | mg/1 |
Substance Name | CEFIXIME |
Labeler Name | REMEDYREPACK INC. |
Pharmaceutical Class | Cephalosporin Antibacterial [EPC], Cephalosporins [CS] |
DEA Schedule | n/a |
Marketing Category | ANDA |
Application Number | ANDA210574 |
Listing Certified Through | 2024-12-31 |
Package
NDC 70518-2749-05 (70518274905)
NDC Package Code | 70518-2749-5 |
---|---|
Billing NDC | 70518274905 |
Package | 2 POUCH in 1 BOX (70518-2749-5) / 1 CAPSULE in 1 POUCH (70518-2749-4) |
Marketing Start Date | 2023-07-07 |
NDC Exclude Flag | N |
Pricing Information | N/A |